DIASORIN IRELAND LIMITED – Trademark Portfolio
Entity Type: 99
DIASORIN IRELAND LIMITED holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include B BIOTRIN. The owner is based in CO. DUBLIN.
INDUSTRIAL, PARK, BLACKROCK
13/14 HOLLY AVENUE, STILLORGAN
CO. DUBLIN , IE
Showing of trademarks Trademarks
Trademark Classifications
DIASORIN IRELAND LIMITED's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does DIASORIN IRELAND LIMITED have?
DIASORIN IRELAND LIMITED has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.
What trademark classes does DIASORIN IRELAND LIMITED file in?
DIASORIN IRELAND LIMITED files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are DIASORIN IRELAND LIMITED's most well-known trademarks?
DIASORIN IRELAND LIMITED's registered trademark portfolio includes well-known marks such as B BIOTRIN. These are among 1 currently registered trademark in the portfolio.
What is DIASORIN IRELAND LIMITED's trademark registration success rate?
DIASORIN IRELAND LIMITED has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.